Mattersight (MATR) Touches $2.60 Formed H&S; Last Week Cara Therapeutics, Inc. (CARA) Analysts

Among 9 analysts covering Cara Therapeutics (NASDAQ:CARA), 8 have Buy rating, 0 Sell and 1 Hold. Therefore 89% are positive. Cara Therapeutics had 21 analyst reports since July 27, 2015 according to SRatingsIntel. As per Tuesday, October 3, the company rating was maintained by Needham. The firm earned “Neutral” rating on Friday, June 30 by Janney Capital. The stock of Cara Therapeutics, Inc. (NASDAQ:CARA) earned “Buy” rating by H.C. Wainwright on Thursday, June 22. The company was maintained on Wednesday, June 21 by Needham. The firm earned “Buy” rating on Friday, August 4 by H.C. Wainwright. The rating was maintained by Canaccord Genuity on Friday, August 4 with “Buy”. The stock of Cara Therapeutics, Inc. (NASDAQ:CARA) has “Buy” rating given on Wednesday, June 21 by Stifel Nicolaus. The firm has “Buy” rating given on Thursday, July 13 by H.C. Wainwright. Laidlaw maintained it with “Buy” rating and $3000 target in Friday, June 30 report. The firm earned “Buy” rating on Wednesday, November 4 by Cantor Fitzgerald. See Cara Therapeutics, Inc. (NASDAQ:CARA) latest ratings:

03/10/2017 Broker: Needham Rating: Buy New Target: $23.0 Maintain
04/08/2017 Broker: Canaccord Genuity Rating: Buy New Target: $25.0000 Maintain
04/08/2017 Broker: Piper Jaffray Rating: Buy New Target: $27.0000 Maintain
03/08/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $20.0000 Maintain
04/08/2017 Broker: H.C. Wainwright Rating: Buy New Target: $30.0000 Maintain
13/07/2017 Broker: H.C. Wainwright Rating: Buy New Target: $30.0000 Maintain

Mattersight Corporation (MATR) formed inverse H&S with $2.70 target or 4.00% above today’s $2.60 share price. Mattersight Corporation (MATR) has $85.10M valuation. The stock increased 1.96% or $0.05 during the last trading session, reaching $2.6. About 24,195 shares traded. Mattersight Corporation (NASDAQ:MATR) has declined 29.56% since January 4, 2017 and is downtrending. It has underperformed by 46.26% the S&P500.

Analysts await Mattersight Corporation (NASDAQ:MATR) to report earnings on February, 14. They expect $-0.10 EPS, up 23.08% or $0.03 from last year’s $-0.13 per share. After $-0.10 actual EPS reported by Mattersight Corporation for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Investors sentiment increased to 1.25 in Q3 2017. Its up 0.43, from 0.82 in 2017Q2. It is positive, as 4 investors sold Mattersight Corporation shares while 4 reduced holdings. 3 funds opened positions while 7 raised stakes. 9.33 million shares or 1.65% less from 9.49 million shares in 2017Q2 were reported. S Squared Tech holds 1.11% of its portfolio in Mattersight Corporation (NASDAQ:MATR) for 467,927 shares. Retail Bank Of America De, a North Carolina-based fund reported 135 shares. Susquehanna Int Grp Ltd Liability Partnership accumulated 23,161 shares. Wells Fargo & Mn reported 7,996 shares. Howe Rusling owns 352 shares or 0% of their US portfolio. Bank & Trust Of New York Mellon Corporation stated it has 12,897 shares. Geode Cap Mgmt Limited Liability Com invested 0% in Mattersight Corporation (NASDAQ:MATR). Bridgeway Inc stated it has 166,796 shares or 0.01% of all its holdings. Goldman Cap Mgmt Inc holds 4.28% of its portfolio in Mattersight Corporation (NASDAQ:MATR) for 1.62 million shares. Northern Tru Corporation reported 39,738 shares or 0% of all its holdings. Royal National Bank & Trust Of Canada accumulated 0% or 18 shares. Penn Cap Mgmt reported 1.12M shares stake. Blackrock Inc reported 325,401 shares. Investor holds 2.84M shares or 0.51% of its portfolio. Fifth Third Fincl Bank accumulated 0% or 1,000 shares.

Among 2 analysts covering Mattersight (NASDAQ:MATR), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Mattersight had 3 analyst reports since November 5, 2015 according to SRatingsIntel. The firm earned “Mkt Outperform” rating on Tuesday, December 15 by JMP Securities. The stock has “Buy” rating by Lake Street on Thursday, November 5.

Investors sentiment decreased to 0.85 in Q3 2017. Its down 0.76, from 1.61 in 2017Q2. It is negative, as 22 investors sold Cara Therapeutics, Inc. shares while 31 reduced holdings. 20 funds opened positions while 25 raised stakes. 17.83 million shares or 4.68% less from 18.71 million shares in 2017Q2 were reported. National Bank Of Montreal Can holds 0% of its portfolio in Cara Therapeutics, Inc. (NASDAQ:CARA) for 63,505 shares. Perigon Wealth Ltd Llc reported 60 shares stake. Cambridge Research Inc stated it has 0% in Cara Therapeutics, Inc. (NASDAQ:CARA). Horrell Mngmt Inc stated it has 0% of its portfolio in Cara Therapeutics, Inc. (NASDAQ:CARA). 434,500 were reported by Franklin. Bank & Trust Of America Corp De invested 0% of its portfolio in Cara Therapeutics, Inc. (NASDAQ:CARA). Commonwealth Equity Services holds 38,867 shares. Parametric Port Assocs Ltd Liability Corporation, a Washington-based fund reported 33,521 shares. Quantbot Ltd Partnership holds 988 shares. Moreover, Morgan Stanley has 0% invested in Cara Therapeutics, Inc. (NASDAQ:CARA). Alliancebernstein L P, a New York-based fund reported 38,600 shares. Stifel invested in 64,400 shares or 0% of the stock. Tci Wealth Advsrs Inc has 175 shares for 0% of their portfolio. 17,914 are owned by American. Moreover, Federated Pa has 0% invested in Cara Therapeutics, Inc. (NASDAQ:CARA) for 39,695 shares.

Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors in the United States. The company has market cap of $440.87 million. It is developing product candidates that target the body's peripheral nervous system. It currently has negative earnings. The companyÂ’s lead product candidate comprises I.V.

Since August 4, 2017, it had 0 buys, and 1 sale for $45,000 activity. The insider Menzaghi Frederique Ph.D. sold $45,000.